NCT06743945View on ClinicalTrials.gov

POLA-R-CHP in the First-line Treatment of Transformed DLBCL

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 17, 2025

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2029

Conditions
Transformed Lymphoma
Interventions
DRUG

POLA-R-CHP

Pola-R-CHP is a combination of rituximab, cyclophosphamide, doxorubicin, prednisone, and polatuzumab vedotin

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER